Graff on Using the Signatera Assay to Assess ctDNA in Early Breast Cancer
December 8th 2023Stephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.
Watch
Safety Data From the Phase 2B SunRISe-2 Study of TAR-200 in BCG-Unresponsive High-Risk NMIBC
December 7th 2023The TAR-200 treatment has demonstrated a favorable safety profile in clinical trial, with primarily low-grade irritated voiding symptoms that are manageable and expected with intravesical therapy, without concerning systemic side effects, making it a promising new option to delay or reduce radical cystectomy in patients with BCG-unresponsive NMIBC.
Watch
Overview of the Mechanism of Action of TAR-200 in Patients With BCG-Unresponsive High-Risk NMIBC
December 7th 2023The TAR-200 treatment for BCG-unresponsive NMIBC works through a catheter-placed intravesical device that elutes gemcitabine over 3 weeks, providing a high complete response rate of 77% in early testing, likely due to the sustained release mechanism.
Watch
Current Standard-of-Care Treatment for Patients With BCG-Unresponsive High-Risk NMIBC
November 30th 2023BCG-unresponsive NMIBC treatment aims to eradicate disease or prolong disease-free intervals, with radical cystectomy as gold standard; newer options like pembrolizumab and gemcitabine/docetaxel provide improved alternatives, though logistic challenges remain.
Watch